Lund, Sweden

Genovis Ab

Calculating rank
USPTO Granted Patents = 9

% Expired Patents = 44.4



Trademarks = 11

Forward Citations = 8

Loading Chart...
Loading Chart...

24 inventors (with patents filed for the assignee):

goldMedal Fredrik Olsson (3 out of 4 patents)

silverMedal Malin Mejare (3 out of 3 patents)

bronzeMedal Lars Björck (2 out of 12 patents)

4.  Per Åkesson (2 out of 6 patents)

5.  Mattias Collin (2 out of 4 patents)

6.  Maria Allhorn (2 out of 3 patents)

7.  Fredrik Leo (2 out of 2 patents)

8.  Stephan Bjork (2 out of 2 patents)

9.  Falk Nimmerjahn (1 out of 3 patents)

10.  Jonathan Sjögren (1 out of 2 patents)

11.  Sylvia Koivunen (1 out of 1 patent)

12.  Sarah Fredriksson (1 out of 1 patent)

13.  Hanna-Karin Toftevall (1 out of 1 patent)

14.  Anders Olin (1 out of 1 patent)

15.  Anders Sjohölm (1 out of 1 patent)


9 patents:

Company Overview
Genovis is a Swedish biotechnology company that specializes in developing and supplying enzymes for the research and biopharma industries. With a focus on proteomics and antibody engineering, Genovis offers cutting-edge solutions for protein analysis and modification. Their innovative products enable researchers to work more efficiently and achieve higher quality results. Genovis is committed to advancing the field of life sciences through continuous innovation and collaboration.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

9 Patents

#52 in Lund

#652 in Sweden

Lund, SE
Lund, Sweden
Forward Citations = 8

24 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genovis Ab. Retrieved from https://idiyas.com/company/genovis-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…